Union Agriculture Minister Shivraj Singh Chouhan had launched the vaccine in Bhopal and announced a ₹300-crore animal disease research laboratory
Union Agriculture Minister Shivraj Singh Chouhan had launched the vaccine in Bhopal and announced a ₹300-crore animal disease research laboratory

India unveils first indigenous H5N1 bird flu vaccine for chickens at ₹1–2 per dose

The ICAR-NIHSAD-developed vaccine had targeted a highly pathogenic H5N1 variant responsible for major poultry outbreaks across the country

India on Friday unveiled its first indigenously developed vaccine against a highly pathogenic strain of H5N1 bird flu affecting chickens, with Union Agriculture Minister Shivraj Singh Chouhan launching the vaccine in Bhopal at an estimated cost of just ₹1–2 per dose.

Developed by scientists at the ICAR-National Institute of High Security Animal Diseases (NIHSAD), the vaccine specifically targets the H5N1 Clade 2.3.2.1a virus, which has been associated with major outbreaks of avian influenza in India's poultry population.

The development is expected to strengthen disease prevention in the poultry industry, which has suffered repeated financial losses from bird flu outbreaks, mass culling of infected birds and restrictions on poultry movement and trade.

The vaccine has been developed domestically to address the absence of a commercially available vaccine specifically targeting this variant. Its low proposed price is intended to make preventive protection affordable for small and marginal poultry farmers.

The launch also included the announcement of a new animal disease research laboratory in Bhopal, with an estimated investment of ₹300 crore, aimed at expanding India's capabilities in veterinary research, disease surveillance and vaccine development.

𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐬 𝐝𝐚𝐧𝐠𝐞𝐫𝐨𝐮𝐬 𝐇𝟓𝐍𝟏 𝐯𝐚𝐫𝐢𝐚𝐧𝐭

The newly developed vaccine targets Clade 2.3.2.1a of the H5N1 virus, a genetically distinct group associated with highly pathogenic avian influenza outbreaks among chickens.

Bird flu is a contagious viral disease that affects domestic poultry and wild birds. Highly pathogenic forms can spread rapidly through susceptible flocks, causing severe illness and mortality rates approaching 100 per cent.

The disease can spread through contact with infected birds, contaminated equipment, feed, water and other materials exposed to the virus.

Outbreaks often require strict containment measures, including movement restrictions, disinfection, surveillance and the culling of infected or exposed birds.

These interventions can cause considerable financial losses for poultry farmers, particularly those operating small farms with limited resources.

The indigenous vaccine uses an inactivated formulation, meaning the virus used in its preparation has been rendered non-infectious while retaining components capable of stimulating an immune response.

Such vaccines are designed to help vaccinated birds develop protection against disease without exposing them to a replicating vaccine virus.

The formulation has been developed to provide protection against the H5N1 Clade 2.3.2.1a strains circulating in India.

𝐎𝐯𝐞𝐫 𝟓𝟎𝟎 𝐛𝐢𝐫𝐝 𝐟𝐥𝐮 𝐨𝐮𝐭𝐛𝐫𝐞𝐚𝐤𝐬 𝐬𝐢𝐧𝐜𝐞 𝟐𝟎𝟎𝟔

India has recorded more than 500 outbreaks involving the H5N1 and H5N8 subtypes of avian influenza since the disease was first detected in the country in 2006.

The first major outbreak was reported in Navapur, Maharashtra, where approximately 10 lakh chickens died, while large numbers of additional birds were culled to contain the infection.

Subsequent outbreaks have repeatedly affected poultry farms, resulting in substantial economic losses and disruption to the livelihoods of farmers.

In 2021, approximately nine lakh chickens died during outbreaks, while another two lakh poultry deaths were reported in 2026.

The 2006 outbreak alone caused estimated direct and indirect economic losses of ₹2,200 crore to ₹3,000 crore.

A separate outbreak in Manipur resulted in losses equivalent to approximately 0.5 per cent of the state's gross domestic product.

Government assessments have indicated that a major uncontrolled bird flu outbreak could threaten more than 20 per cent of India's poultry population and potentially reduce national GDP growth by up to 1.5 per cent.

These estimates highlight the wider economic consequences of animal diseases beyond the immediate loss of infected birds.

𝐋𝐨𝐰-𝐜𝐨𝐬𝐭 𝐩𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐨𝐮𝐥𝐭𝐫𝐲 𝐟𝐚𝐫𝐦𝐞𝐫𝐬

The vaccine's proposed price of ₹1–2 per dose is intended to make it accessible to poultry farmers across different income groups.

Small poultry farmers are particularly vulnerable to disease outbreaks because they may lack the financial resources required for advanced biosecurity measures, regular veterinary monitoring and emergency disease management.

An outbreak can destroy an entire flock within a short period, leaving farmers without their principal source of income.

Even farms that remain unaffected by infection can experience losses when restrictions on poultry transportation, market access and trade are introduced.

Affordable vaccination could reduce the risk of severe disease and help protect poultry production, provided the vaccine is deployed through an appropriate disease-control programme.

However, vaccination alone cannot eliminate the threat of bird flu. Effective prevention also requires disease surveillance, early detection, movement controls, sanitation and strict farm-level biosecurity.

The availability of the vaccine represents an additional preventive tool rather than a replacement for existing containment measures.

𝐍𝐞𝐰 ₹𝟑𝟎𝟎-𝐜𝐫𝐨𝐫𝐞 𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝

The launch was accompanied by the announcement of a ₹300-crore state-of-the-art animal disease research laboratory in Bhopal.

The proposed facility is expected to strengthen scientific infrastructure for studying infectious animal diseases and developing preventive technologies.

The ICAR-NIHSAD institute in Bhopal specialises in research on high-risk animal pathogens and operates under strict biosafety protocols.

Its scientists have previously contributed to the development of indigenous vaccines against several important animal diseases, including Gumboro disease, classical swine fever, brucellosis and African swine fever.

The new H5N1 vaccine adds to the institute's work in veterinary immunology, virology and animal disease prevention.

The research team involved in developing the vaccine included Dr S Nagarajan, Dr Manoj Kumar, Dr C Tosh, Dr H V Murugkar, Dr Aniket Sanyal, Dr Senthil Kumar D, Dr Naveen Kumar and Dr Yogisharadhya R.

The development process involved prolonged laboratory research and adherence to stringent biosafety requirements because of the risks associated with highly pathogenic avian influenza viruses.

𝐁𝐢𝐫𝐝 𝐟𝐥𝐮 𝐚𝐥𝐬𝐨 𝐩𝐨𝐬𝐞𝐬 𝐡𝐮𝐦𝐚𝐧 𝐡𝐞𝐚𝐥𝐭𝐡 𝐫𝐢𝐬𝐤𝐬

Although H5N1 primarily affects birds, certain strains can infect mammals and humans, making the disease an important concern for public health authorities.

Human infections are uncommon but can cause severe illness, particularly following close or prolonged exposure to infected birds or contaminated environments.

According to World Health Organization figures cited by the Agriculture Ministry, 1,003 human cases of H5N1 infection, including 479 deaths, have been reported across 25 countries since 2003.

The H5N1 Clade 2.3.2.1a variant has also been detected in mammals, with three human infections associated with the strain.

These developments have increased the importance of monitoring avian influenza viruses and limiting their circulation in domestic poultry populations.

Reducing infections among chickens may also help decrease opportunities for transmission to other animals and humans.

However, the newly developed vaccine is intended for chickens and is not a vaccine for human use.

Public health authorities continue to emphasise surveillance, safe handling of poultry, protective measures for exposed workers and prompt reporting of suspected infections.

𝐀𝐧𝐢𝐦𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐜𝐚𝐮𝐬𝐞 𝐦𝐚𝐣𝐨𝐫 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐥𝐨𝐬𝐬𝐞𝐬

The development comes amid wider efforts to reduce the economic burden of infectious diseases affecting India's livestock and poultry sectors.

Animal husbandry provides an important source of supplementary income for millions of rural households, particularly small and marginal farmers.

Several major animal diseases continue to cause substantial financial losses through reduced productivity, livestock mortality, treatment expenses and restrictions on animal movement.

Government estimates place annual losses from Foot and Mouth Disease at approximately ₹22,000 crore, while Lumpy Skin Disease accounts for another ₹20,000 crore.

Brucellosis causes estimated losses of ₹9,212 crore, while Peste des Petits Ruminants, a disease affecting sheep and goats, results in losses of around ₹4,683 crore.

Together, these diseases account for approximately ₹56,000 crore in estimated economic losses.

Vaccination programmes have consequently become a central component of the country's animal health strategy.

Under the National Animal Disease Control Programme, more than 147 crore free vaccine doses have been administered against Foot and Mouth Disease.

Following the severe Lumpy Skin Disease outbreak in 2022, which infected approximately 32.8 lakh animals and caused 1.86 lakh deaths, Indian scientists developed an indigenous vaccine known as Lumpi-ProVacInd.

The latest bird flu vaccine forms part of this broader effort to strengthen domestic disease-control capabilities.

𝐈𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐬𝐮𝐫𝐯𝐞𝐢𝐥𝐥𝐚𝐧𝐜𝐞 𝐫𝐞𝐦𝐚𝐢𝐧 𝐜𝐫𝐮𝐜𝐢𝐚𝐥

The introduction of the indigenous H5N1 vaccine could provide an additional layer of protection for India's poultry industry, but its effectiveness at the population level will depend on how it is manufactured, distributed and incorporated into disease-control programmes.

Large-scale implementation would require coordination among veterinary authorities, poultry producers, state animal husbandry departments and disease surveillance agencies.

The development of vaccination protocols, monitoring of immune responses and continued tracking of circulating H5N1 variants will also be important.

Avian influenza viruses can undergo genetic changes over time, making regular surveillance necessary to determine whether vaccines remain effective against emerging strains.

Authorities will also need to ensure that vaccination does not weaken existing systems for identifying and reporting infected birds.

Details concerning the vaccine's commercial rollout, production capacity and nationwide deployment schedule have yet to be fully established.

For India's poultry sector, the availability of a domestically developed vaccine at a proposed cost of ₹1–2 per dose represents a significant development in preventive animal healthcare.

Its wider impact will depend on sustained scientific monitoring, affordable access for farmers and integration with existing biosecurity and disease-control measures.

Responsive Banner